tbuckley/cabot-search huggingface dataset:
Impact of lymphoma survivorship clinic visit on patient-centered outcomes.
Authors: Carrie A. Thompson, Jessica N Towns, Laurie Dripps, Sarah Jenkins, Kandace Lackore, Kathleen J. Yost, Kay Ristow, Joseph Colgan, Thomas Matthew Habermann, David James Inwards, Patrick B. Johnston, Robin Klebig, Yi Lin, Svetomir Markovic, Ivana N. M. Micallef, Grzegorz S. Nowakowski, Luis F. Porrata, Allison Claire Rosenthal, Thomas E. Witzig, Stephen Maxted Ansell
Journal: Journal of Clinical Oncology (2016)

64 Background: The goals of our Lymphoma Survivorship Clinic (SC) are to coordinate care, educate patients, and create a survivorship care plan (SCP). The aim of this study was to determine if patient-centered outcomes are improved after a SC visit. Methods: From 11/13-5/15, surveys were mailed to recently-treated lymphoma patients who were within 4 weeks of their last visit and in remission. Quality of life (QOL) was measured with PROMIS and distress was measured with the Impact of Events scale. Responses between those who attended SC and those who were eligible but did not attend were analyzed. Results: There were 96 surveys sent to the SC group; 59 were returned (61% response rate). Of the non-SC group, 140 surveys were sent and 84 were returned (60% response rate). Mean age was 57 years (range 23-77) in the SC group and 59 years (23-88) in the non-SC group. There were more females in the SC group (52% vs 30%) but no differences in race, marital status, education, or health literacy. Those who attended the SC were more likely to recall receiving a summary of cancer treatment and recommendations for follow-up care (90% SC vs. 75% non-SC, p = 0.03). Furthermore, SC attendees were more likely to “definitely” recall discussion on improving health or preventing illness (89% vs. 53%), getting help in making changes in habits/lifestyle (76% vs. 50%), diet (80% vs. 31%), and exercise (82% vs. 51%), all p &lt; 0.001. There were no differences in discussions regarding smoking, follow-up testing, and symptom monitoring. The SC group was less likely to need more information regarding sexuality (6% vs 20%, p = 0.045). There were no differences in need for information regarding anxiety, fitness, familial cancer risk, fertility, complementary therapies, and social issues. The SC group was slightly more confident that they could get information or advice related to cancer (completely confident 76% vs. 61%, p = 0.07). There were no differences in QOL or distress. Conclusions: A Lymphoma SC visit increased receipt of SCP and provided more information on survivorship issues, particularly health behaviors, but did not improve QOL or distress. Further study is needed to determine if this leads to long-term health benefits.
Effect of Certain Sulfur-Containing Compounds on the Initiation of Mitosis in Amoeba proteus
Authors: Chalkley, Harold W.
Journal: JNCI Journal of the National Cancer Institute (1942)

Journal Article Effect of Certain Sulfur-Containing Compounds on the Initiation of Mitosis in Amoeba proteus Get access Harold W. Chalkley Harold W. Chalkley senior physiologist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 2, Issue 5, April 1942, Pages 425–447, https://doi.org/10.1093/jnci/2.5.425 Published: 01 April 1942
Association of Human Papillomavirus Vaccine With the Development of Keratinocyte Carcinomas
Authors: Anna J. Nichols, Amber Heyna Allen, Shahjahan Shareef, Evangelos V. Badiavas, Robert S. Kirsner, Tim Ioannides
Journal: JAMA Dermatology (2017)

Keratinocyte carcinomas (KCs), consisting of squamous cell carcinomas (SCCs) and basal cell carcinomas (BCCs), are the most common human malignant neoplasms. Several risk factors have been implicated in KC development. For some SCCs, particularly those in immunocompromised patients, human papillomavirus (HPV) may be an important factor.To determine whether quadrivalent HPV vaccination would affect the development of KCs in immunocompetent patients with a history of multiple KCs.Two patients with a history of multiple KCs-a man in his 70s (patient 1) and a woman in her 80s (patient 2)-were treated in a private dermatology practice. Each patient received 3 doses of the quadrivalent HPV vaccine at 0, 2, and 6 months in 2013, and both patients underwent full-body skin examinations at least every 3 months. Biopsy-proven skin cancers were recorded for 16 months (for patient 1) or 13 months (for patient 2) after the first dose of vaccine and then compared with the number of biopsy-proven skin cancers recorded over a similar period before the first dose of vaccine. The period of observation was from October 18, 2011, to June 21, 2014.The numbers of new SCCs and BCCs after the first dose of the quadrivalent HPV vaccine.Patient 1 had a mean of 12 new SCCs and 2.25 new BCCs per year before vaccination. After vaccination, he developed 4.44 SCCs and 0 BCCs per year, a 62.5% reduction in SCCs and a 100% reduction in BCCs. Patient 2 had a mean of 5.5 new SCCs and 0.92 new BCCs per year before vaccination. After vaccination, she developed 1.84 SCCs and 0 BCCs per year, a 66.5% reduction in SCCs and a 100% reduction in BCCs. The quadrivalent HPV vaccine was well tolerated by both patients and had no adverse effects.A reduction of SCCs and BCCs was observed in 2 patients after administration of the quadrivalent HPV vaccine. These findings highlight the possibility that cutaneous SCC development, and perhaps BCC development, may be driven in part by HPV in immunocompetent patients. Human papillomavirus vaccination may represent an efficacious, cost-effective, readily available, and well-tolerated strategy for preventing KCs.
Breast-Feeding Mediates Feto-Maternal Tolerance and Improves Outcome of Allogeneic Bone Marrow Transplantation.
Authors: Kazutoshi Aoyama, Ken-ichi Matsuoka, Daigo Hashimoto, Tatsuo Ichinohe, Mine Harada, Mitsune Tanimoto, Takanori Teshima
Journal: Blood (2007)
ニフェジピンCR+バルサルタンおよびアムロジピン+バルサルタンでの治療による早朝高血圧の予防と腎臓保護の有効性の比較(MONICA研究)
Authors: Tanaka Toru, Miura Shinichiro, Tanaka Masatoshi, Hirano Tadashi, Saku Keijiro
Journal: Circulation (2013)
High Expression of Human Leukocyte Formin Protein in T Non-Hodgkin’s Lymphomas and in CD19− Cell Population of Normal Tonsils.
Authors: Patricia M.B. Favaro, Fabiola Traina, Marta Crespo, Francesc Bosch, Pierre Brousset, George Delsol, Fernando F. Costa, Sara T.O. Saad
Journal: Blood (2005)
Phase II study of vorinostat (V) in combination with idarubicin and high-dose cytarabine (IA) as front-line therapy in patients (pts) with high-risk myelodyplsatic syndrome (MDS) or acute myeloid leukemia (AML)
Authors: E. Jabbour, S. Faderl, F. Ravandi, M. Konopleva, S. Verstovsek, J. Cortes, W. Wierda, W. M. Newsome, H. Yang, H. Kantarjian, G. Garcia-Manero
Journal: Journal of Clinical Oncology (2009)

7004 Background: Standard induction therapy for pts with AML has not changed over the last 2 decades nor has the outcome of these pts. We demonstrated in vitro and ex vivo that the combination of an histone deacetylase inhibitor with anthraycline is synergistic (Blood 2006;108:1174); an effect that could be mediated by activation of DNA damage/repair pathways, and found that such combination is safe in phase 1 trial (Blood 2007;110:1842). We designed a phase II study of V with IA as front-line therapy for MDS/AML. Methods: Pts with untreated int-2/high-risk MDS or AML ages 15–65 with adequate liver and renal functions and PS, and EF ≥ 50% were eligible. Pts with CBF were excluded. Initial dose of V was 500 mg orally TID for 3 days followed on day 4 by IA (I:12 mg/m 2 /dx3; A:1.5g/m 2 /dx4 over 24 hrs). After induction and if in CR, pt can receive 5 cycles of consolidation with V at the same dose and IA (I:8 mg/m 2 /dx2; A:0.75g/m 2 /dx3 over 24 hours) followed by 1 year of maintenance with V. The study was powered to demonstrate improvement in PFS at 7 months and acceptable toxicity. Prior to formal initiation of the phase II, the study had a “run-in” phase to confirm the safety of the triple combination. Correlative studies include analysis of DNA repair/damage pathways. Results: 22 pts have been registered. 3 pts with relapsed/refractory AML were treated in the run-in phase. No excess toxicity was observed; 2 achieved CR and 1 CRp. Following these, 19 pts were enrolled on the phase 2 portion. 17 pts were evaluable. Median age was 49 years. Median WBC at presentation was 12.75 x 10 9 /L. Cytogenetic analysis were abnormal in 12 (71%), complex in 10 (59%). 8 (47%) had secondary disease. 4 (23%) were Flt-3 positive. No unexpected grade 3/4 toxicities have been observed. The CR rate was 82%. 1 pt acheived a marrow CR and 2 pts died during induction. CR were universally associated with CG response. All Flt-3+ pts achieved a CR. Only 2 pts (14%) have relapsed (4 and 5 months). The median PFS has not been reached. Conclusions: The combination of IA and V is safe and active in AML/MDS. No stopping rule has been met. Results will be compared with those of a parallel IA study at MDACC. Correlative analysis are ongoing. [Table: see text]
Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)—CheckMate 714
Authors: R. Haddad, M. Gillison, R.L. Ferris, K. Harrington, M. Monga, C. Baudelet, W.J. Geese, A. Argiris
Journal: Annals of Oncology (2016)
Distinctive Spectra of Cytogenetic Alterations in Over Five Hundred East Asian Patients with Acute Leukemia
Authors: Hyun-Jung Choi, Hye Ran Kim, Myung-Geun Shin, Jong-Hee Shin, Bock-Hee Park, Dong-Wook Ryang, Soon-Pal Suh
Journal: Blood (2011)
Filling in the gaps: estimating numbers of chlamydia tests and diagnoses by age group and sex before and during the implementation of the English National Screening Programme, 2000 to 2012
Authors: Nastassya L Chandra, Kate Soldan, Ciara Dangerfield, Bersabeh Sile, Stephen Duffell, Alireza Talebi, Yoon H Choi, Gwenda Hughes, Sarah C Woodhall
Journal: Eurosurveillance (2017)

To inform mathematical modelling of the impact of chlamydia screening in England since 2000, a complete picture of chlamydia testing is needed. Monitoring and surveillance systems evolved between 2000 and 2012. Since 2012, data on publicly funded chlamydia tests and diagnoses have been collected nationally. However, gaps exist for earlier years. We collated available data on chlamydia testing and diagnosis rates among 15-44-year-olds by sex and age group for 2000-2012. Where data were unavailable, we applied data- and evidence-based assumptions to construct plausible minimum and maximum estimates and set bounds on uncertainty. There was a large range between estimates in years when datasets were less comprehensive (2000-2008); smaller ranges were seen hereafter. In 15-19-year-old women in 2000, the estimated diagnosis rate ranged between 891 and 2,489 diagnoses per 100,000 persons. Testing and diagnosis rates increased between 2000 and 2012 in women and men across all age groups using minimum or maximum estimates, with greatest increases seen among 15-24-year-olds. Our dataset can be used to parameterise and validate mathematical models and serve as a reference dataset to which trends in chlamydia-related complications can be compared. Our analysis highlights the complexities of combining monitoring and surveillance datasets.
Pegfilgrastim for patients with malignant lymphoma in our hospital
Authors: Hiroyuki Muranushi, Atsushi Ueda, Ryosuke Takaya, Shinichi Ochi, Takashi Nagayama, Kazuya Okada, Aki Sato, Takayuki Sato, Takeshi Maeda, Tatsuhito Onishi, Yasunori Ueda
Journal: Annals of Oncology (2016)
The University of Southern California penile cancer experience: Clinicopathologic characteristics of patients from 1991 to 2011.
Authors: Isuru Sampath Jayaratna, Rachel L. Schwartz, Anirban Pradip Mitra, Jie Cai, Yanling Ma, David I. Quinn, Tanya B. Dorff, Anne Schuckman
Journal: Journal of Clinical Oncology (2012)

342 Background: Penile squamous cell carcinoma (PSCC) is a disfiguring and deadly disease. USCS data has shown an increased incidence in specific US minority communities. Methods: After IRB approval, a retrospective review of patients treated for PSCC at LAC-USC Medical Center, USC University Hospital, and Norris Comprehensive Cancer Center from 1991 to 2011 was completed. Patient characteristics were evaluated with descriptive statistics and contingency analyses. Results: Of 69 patients identified with PSCC, 64 had surgical staging information available. Median follow up was 18 months (range 0 – 161). Median age at diagnosis was 50 (range 23–86), with 50.7% of patients ≥50 and 49.3% &lt;50 at diagnosis. Hispanic patients represented 71% (n=44) of our cohort. 44 patients underwent partial penectomy, 10 total penectomy and 8 had [1]a diagnostic biopsy. T stage distribution was Tis: 7.8% (n=5), T1: 39.1% (n=25), T2: 29.7% (n=19), T3: 18.8% (n=12), T4: 1.6% (n=1) and unknown: 3.1% (n=2). 38 groins were surgically evaluated, and 14 pelvic lymph node dissections were performed. Of the 24 patients who underwent a surgical lymph node evaluation. The N stage distribution was N1: 41.7% (n=10), N2: 12.5% (n=3) and N3: 45.8% (n=11). Median lymph node yield in groin dissections was 11, with a lymph node positivity rate of 49%. 30.8% (n=20), 41.5% (n=27), 12.3% (n=8) and 15.4% (n=10) of patients had well, moderately, poorly differentiated PSCC or unknown grade, respectively. There was no association of age (p=0.16) or race (p=0.24) with clinical stage. Stage was significantly associated with grade (p=0.049), with 75% of poorly differentiated tumors being Stage 4, compared with 21.4% of well-moderately differentiated tumors. Conclusions: In our cohort, we found a primarily Hispanic ethnic prevalence, which is reflective of our patient population, as well as a younger age at diagnosis in contrast to previously published reports. We observed a higher average stage in both T and N stages in our population compared with national averages. It is noted that the small sample size limits our power to draw conclusions, however this initial description of our population suggests variation in the disease process that may be related to demographic factors.
Secondhand Smoke Exposure in Early Life and Food-Related Symptoms through Adolescence: Population-Based Prospective Cohort Study
Authors: Laura Feldman, Jesse Thacher, Marianne van Hage, Erik Melén, Göran Pershagen, Magnus Carl Wickman, Teresa To, Jennifer L. Protudjer, Anna Bergström
Journal: Journal of Allergy and Clinical Immunology (2017)
The Use of Recombinant Activated Factor VII for Controlling Bleeding in Pediatric Patients Undergoing Invasive Surgeries.
Authors: Ampaiwan Chuansumrit, Sumate Teeraratkul, Sukasom Attanawanich, Pracha Nantnarumit, Suradej Hongeng, Suthep Wanitkun, Junya Jirapradittha, Mali Rungreungvanich, Taweesak Janwityanujit, Teerachai Chantarojanasiri
Journal: Blood (2004)
Single-fraction high-dose-rate (HDR) brachytherapy boost and hypofractionated radiation for intermediate- and high-risk prostate cancer: A report of toxicity from a single center experience.
Authors: Claire Arthur, Nooreen Sarah Alam, Paula Mandall, Ric Swindell, P. Anthony Elliott, Anna Tran, Jacqueline E. Livsey, Ananya Choudhury, John P. Logue, James Wylie
Journal: Journal of Clinical Oncology (2012)

112 Background: Single-fraction HDR brachytherapy offers a highly conformal approach to dose escalation for intermediate and high risk prostate cancer and exploits the apparent low α/β ratio of prostate cancer cells. The potential benefit of improving tumour control must be balanced against the heightened risk of toxicity. We assessed and compared toxicity among patients receiving either 12.5 Gy or 15 Gy as a single fraction HDR boost prior to conformal external beam radiotherapy (EBRT). Methods: Between July 2008 and February 2011, 177 patients received HDR brachytherapy prior to conformal EBRT (37.5 Gy in 15 fractions). 95 patients in the early cohort received 12.5 Gy and 82 patients in the later cohort received 15 Gy. The median patient age at presentation was 67 (range 57 – 77) with a median PSA of 16.0 (range 0.29 – 102), median Gleason score 7 (range 6 – 10), clinical stages T1c to T4 and median baseline IPSS was 8 (range 0 – 27). Prospective patient questionnaires - IPSS, LENT SOMA and EPIC QoL - were completed prior to treatment and at regular intervals following EBRT (6 weeks, 6 monthly thereafter). Results: Both treatment groups had similar median IPSS values at 6 weeks (12.5 Gy = 10, 15 Gy = 11); there was no significant difference in values throughout follow-up. Mean LENT SOMA scores for bladder/urethra toxicity peaked at 6 weeks (12.5 Gy = 0.6, 15 Gy = 0.72) with no trend towards greater reporting of maximum values of ≥ 2 in the 15 Gy cohort. Rectum/bowel mean LENT SOMA scores peaked at 6 weeks (12.5 Gy = 0.30, 15 Gy = 0.39). Although a greater proportion of 15 Gy patients reported a maximum score of ≥ 2 at 6 weeks and 6 months compared with the 12.5 Gy patients, this returned to pre-treatment levels at 12 months. Conclusions: We conclude that dose escalation from 12.5 Gy to 15 Gy delivered in a single HDR fraction is not associated with a clinically significant increase in toxicity. We believe that the reported toxicity is acceptable at this level of dose escalation (2 Gy equivalent = 112 Gy, assuming an α/β ratio of 1.5). Ongoing follow-up is required to ascertain tumour control.
IMST-53. THE EFFICACY OF CD133 BiTEs AND CAR-T CELLS IN PRECLINICAL MODEL OF RECURRENT GLIOBLASTOMA
Authors: Parvez Vora, Chirayu Chokshi, Maleeha Qazi, Chitra Venugopal, Sujeivan Mahendram, Mohini Singh, Jarrett Adams, Max London, David Bakhshinyan, Minomi Subapanditha, Nicole McFarlane, James Pan, Jonathan Bramson, Jason Moffat, Sachdev Sidhu, Sheila Singh
Journal: Neuro-Oncology (2016)

Glioblastoma (GBM) is a uniformly fatal primary brain tumor, characterized by extensive cellular heterogeneity. Numerous studies have implicated CD133+ brain tumor initiating cells (BTICs) as drivers of chemo- and radio-resistance in GBM. We have recently demonstrated that a CD133-driven gene signature is predictive of poor overall survival and targeting CD133+ treatment-refractory cells may be an effective strategy to block GBM recurrence. Chimeric antigen receptors (CARs) and bispecific T-Cell engaging antibodies (BiTEs) present promising immunotherapeutic approaches that have not yet been validated for recurrent GBM. Using CellectSeq, a novel methodology that combines use of phage-displayed synthetic antibody libraries and DNA sequencing, we developed the CD133-specific monoclonal antibody ‘RW03’. We constructed CD133-specific BiTEs that consist of two arms; one recognizes the tumor antigen (CD133) and the second is specific to CD3 antigen that bind to human GBMs and PBMC-derived T cells, respectively. We observed BiTEs redirecting T cells to kill GBMs, with greater efficiency observed in CD133high GBMs, validating BiTE target specificity. Incubating T-cells with BiTEs and the CD133high GBMs resulted in increased expression of T cell activation markers. In parallel, we derived the single chain variable fragment (scFv) from RW03, added a myc-tag and generated a second-generation CAR with ΔNGFR as a selection marker. CD133-specific CAR-T cells were cytotoxic to CD133+ GBMs. Co-culturing CD133 CAR-T cells with GBMs triggered T cell activation and proliferation. Treatment of GBM tumor-bearing mice with CD133-specific CAR-T cells yielded extended survival in mice and significant reductions in brain tumor burden. Furthermore, we uniquely adapted the existing chemoradiotherapy protocol for GBM patients for treatment of immunocompromised mice engrafted with human GBMs. Within this model, we have initiated treatment of recurrent GBM directed against CD133+ BTICs, to allow for a direct prospective comparison of toxicity and efficacy of BiTEs and CAR T cell strategies.
Safety and Efficacy of the Combination of Bortezomib with the Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Trial.
Authors: Miles Prince, Hang Quach, Paul Neeson, Mitch Keegan, Michael Copeman, Stefan Peinert, Mark Bishton, Max Wolf, David Ritchie, John F. Seymour, Dennis Carney, David Westerman, Simon Harrison
Journal: Blood (2007)
High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia.
Authors: Masamitsu Yanada, Jin Takeuchi, Isamu Sugiura, Hideki Akiyama, Noriko Usui, Fumiharu Yagasaki, Nobuhiko Emi, Yasushi Miyazaki, Shigeki Ohtake, Itsuro Jinnai, Keitaro Matsuo, Tomoki Naoe, Ryuzo Ohno
Journal: Blood (2005)
Compassionate use program for trifluridine/tipiracil (TAS-102) in metastatic colorectal cancer: a real-life overview
Authors: L. Salvatore, M. Niger, L. Bellu, E. Tamburini, P. Garcia-Alfonso, N. Amellal, A.-S. Delmas, M. Wahba, G. Prager
Journal: Annals of Oncology (2016)
Annals Story Slam - The Last Chocolate Bar
Authors: Rosalind Kaplan
Journal: Annals of Internal Medicine (2017)

Web Exclusives7 February 2017Annals On Being a Doctor Story Slam - The Last Chocolate BarFREERosalind Kaplan, MDRosalind Kaplan, MDFrom Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0016 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - The Last Chocolate Bar "The Last Chocolate Bar," by Rosalind Kaplan, MD (Duration 7:18)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: From Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.Current Author Address: Rosalind Kaplan, MD, Thomas Jefferson University Hospital, Philadelphia, PA; e-mail, [email protected]com. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 February 2017Volume 166, Issue 3Page: SS1KeywordsChocolate ePublished: 7 February 2017 Issue Published: 7 February 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
Retrospective observational analysis of bevacizumab (BV) plus paclitaxel (TXL) as first line treatment in metastatic HER2 negative breast cancer (BC): are BV long responders a different subgroup?
Authors: I. Bertolini, C. De Angelis, L. Diodati, F. Ilaria, M.G. Bianco, A. Fontana, A. Michelotti, B. Salvadori, E. Landucci, E. Pfanner, P. Ferrari, C. Orlandini, A. Falcone
Journal: Annals of Oncology (2016)
Adjuvant chemotherapy in stage II and III resected gastric cancer: clinical data from a single center experience
Authors: M.G. Sauta, M. Squadroni, F. Brena, M. Bonomi, C. Ripa, E. Cerchiaro, G.L. Ceresoli, P. Salvini, G. Beretta
Journal: Annals of Oncology (2016)